{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:14:40Z","timestamp":1779102880575,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["63007497"],"award-info":[{"award-number":["63007497"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1U01AI141919-01"],"award-info":[{"award-number":["1U01AI141919-01"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2017R1C1B2003336"],"award-info":[{"award-number":["NRF-2017R1C1B2003336"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002471","name":"Dongguk University","doi-asserted-by":"publisher","award":["Research fund of 2019"],"award-info":[{"award-number":["Research fund of 2019"]}],"id":[{"id":"10.13039\/501100002471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Zoster vaccines generate antibody responses against varicella-zoster virus (VZV). We compared antibody-dependent cell cytotoxicity (ADCC) elicited by zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV). ADCC mediated by antibodies against VZV lysate (VZV-ADCC) and recombinant glycoprotein E (gE-ADCC) was measured using plasma from 20 RZV- and 20 ZVL-recipients, including half 50\u201360-years-old and half \u226570-years-old. Solid phase-bound anti-VZV antibodies stimulated TNF\u03b1 in NK cells as measured by flow cytometry or ELISA. VZV-ADCC pre- and post-immunization was higher in younger vaccinees. ZVL did not appreciably increase VZV-ADCC, whereas RZV increased VZV-ADCC in older vaccinees. ELISA-measured gE-ADCC was similar across groups pre-immunization; significantly increased after ZVL; and RZV and was higher in younger RZV than ZVL recipients. IgG3 antibodies increased after RZV and ZVL, with greater anti-gE than anti-VZV responses. Moreover, gE-ADCC strongly correlated with anti-gE antibody avidity, but there were no appreciable correlations between VZV-ADCC and avidity. NK cells stimulated by anti-gE antibodies showed increased IFN\u03b3 and CD107a expression, which was not observed with anti-VZV antibodies. In conclusion, anti-gE antibodies generated more robust ADCC than anti-VZV antibodies. RZV induced higher ADCC antibodies than ZVL depending on the antigen and age of vaccinees. Older adults had lower ADCC antibodies before and after vaccination than younger adults.<\/jats:p>","DOI":"10.1038\/s41541-022-00545-2","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T09:04:13Z","timestamp":1666688653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8762-7006","authenticated-orcid":false,"given":"Seong Yeon","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron J.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Canniff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Scott","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6920-0623","authenticated-orcid":false,"given":"Adriana","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"545_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrmicro3215","volume":"12","author":"L Zerboni","year":"2014","unstructured":"Zerboni, L., Sen, N., Oliver, S. L. & Arvin, A. M. Molecular mechanisms of varicella zoster virus pathogenesis. Nat. Rev. Microbiol 12, 197\u2013210 (2014).","journal-title":"Nat. Rev. Microbiol"},{"key":"545_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1086\/528696","volume":"197","author":"MJ Levin","year":"2008","unstructured":"Levin, M. J. et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J. Infect. Dis. 197, 825\u2013835 (2008).","journal-title":"J. Infect. Dis."},{"key":"545_CR3","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1056\/NEJMp058091","volume":"352","author":"A Arvin","year":"2005","unstructured":"Arvin, A. Aging, immunity, and the varicella-zoster virus. N. Engl. J. Med. 352, 2266\u20132267 (2005).","journal-title":"N. Engl. J. Med"},{"key":"545_CR4","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1086\/605611","volume":"200","author":"A Weinberg","year":"2009","unstructured":"Weinberg, A. et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J. Infect. Dis. 200, 1068\u20131077 (2009).","journal-title":"J. Infect. Dis."},{"key":"545_CR5","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1086\/522123","volume":"197","author":"AM Arvin","year":"2008","unstructured":"Arvin, A. M. Humoral and cellular immunity to varicella-zoster virus: an overview. J. Infect. Dis. 197, S58\u2013S60 (2008).","journal-title":"J. Infect. Dis."},{"key":"545_CR6","doi-asserted-by":"publisher","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","volume":"37","author":"H Asada","year":"2019","unstructured":"Asada, H. VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study. Vaccine 37, 6776\u20136781 (2019).","journal-title":"Vaccine"},{"key":"545_CR7","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/infdis\/jiu279","volume":"210","author":"PB Gilbert","year":"2014","unstructured":"Gilbert, P. B. et al. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J. Infect. Dis. 210, 1573\u20131581 (2014).","journal-title":"J. Infect. Dis."},{"key":"545_CR8","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1128\/JCM.38.6.2447-2449.2000","volume":"38","author":"H Kimura","year":"2000","unstructured":"Kimura, H. et al. Comparison of quantitations of viral load in varicella and zoster. J. Clin. Microbiol 38, 2447\u20132449 (2000).","journal-title":"J. Clin. Microbiol"},{"key":"545_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1086\/599381","volume":"200","author":"AK Satyaprakash","year":"2009","unstructured":"Satyaprakash, A. K. et al. Viremia in acute herpes zoster. J. Infect. Dis. 200, 26\u201332 (2009).","journal-title":"J. Infect. Dis."},{"key":"545_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1006\/viro.1993.1543","volume":"196","author":"JE Rodriguez","year":"1993","unstructured":"Rodriguez, J. E., Moninger, T. & Grose, C. Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody. Virology 196, 840\u2013844 (1993).","journal-title":"Virology"},{"key":"545_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jpeds.2004.11.022","volume":"146","author":"A Etzioni","year":"2005","unstructured":"Etzioni, A. et al. Fatal varicella associated with selective natural killer cell deficiency. J. Pediatr. 146, 423\u2013425 (2005).","journal-title":"J. Pediatr."},{"key":"545_CR12","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1086\/378503","volume":"188","author":"O Levy","year":"2003","unstructured":"Levy, O. et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J. Infect. Dis. 188, 948\u2013953 (2003).","journal-title":"J. Infect. Dis."},{"key":"545_CR13","doi-asserted-by":"publisher","first-page":"e0217749","DOI":"10.1371\/journal.pone.0217749","volume":"14","author":"MJ Levin","year":"2019","unstructured":"Levin, M. J., Duchon, J. M., Swamy, G. K. & Gershon, A. A. Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program. PLoS One 14, e0217749 (2019).","journal-title":"PLoS One"},{"key":"545_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/infdis\/147.4.737","volume":"147","author":"JA Zaia","year":"1983","unstructured":"Zaia, J. A. et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J. Infect. Dis. 147, 737\u2013743 (1983).","journal-title":"J. Infect. Dis."},{"key":"545_CR15","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.4049\/jimmunol.136.11.4243","volume":"136","author":"AB Tilden","year":"1986","unstructured":"Tilden, A. B. et al. Demonstration of NK cell-mediated lysis of varicella-zoster virus (VZV)-infected cells: characterization of the effector cells. J. Immunol. 136, 4243\u20134248 (1986).","journal-title":"J. Immunol."},{"key":"545_CR16","first-page":"217","volume":"58","author":"J Babbage","year":"1984","unstructured":"Babbage, J., Sigfusson, A. & Souhami, R. L. Antibody-dependent cell-mediated cytotoxicity to Varicella zoster. Clin. Exp. Immunol. 58, 217\u2013222 (1984).","journal-title":"Clin. Exp. Immunol."},{"key":"545_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1128\/jvi.54.1.98-103.1985","volume":"54","author":"M Ito","year":"1985","unstructured":"Ito, M., Ihara, T., Grose, C. & Starr, S. Human leukocytes kill varicella-zoster virus-infected fibroblasts in the presence of murine monoclonal antibodies to virus-specific glycoproteins. J. Virol. 54, 98\u2013103 (1985).","journal-title":"J. Virol."},{"key":"545_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1128\/iai.33.2.507-511.1981","volume":"33","author":"AA Gershon","year":"1981","unstructured":"Gershon, A. A. & Steinberg, S. P. Inactivation of varicella zoster virus in vitro: effect of leukocytes and specific antibody. Infect. Immun. 33, 507\u2013511 (1981).","journal-title":"Infect. Immun."},{"key":"545_CR19","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/cid\/ciz770","volume":"70","author":"MJ Levin","year":"2020","unstructured":"Levin, M. J. & Weinberg, A. Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine. Clin. Infect. Dis. 70, 1509\u20131515 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"545_CR20","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1093\/infdis\/jiy383","volume":"218","author":"A Weinberg","year":"2018","unstructured":"Weinberg, A. et al. Comparative Immune Responses to Licensed Herpes Zoster Vaccines. J. Infect. Dis. 218, S81\u2013S87 (2018).","journal-title":"J. Infect. Dis."},{"key":"545_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.it.2019.01.005","volume":"40","author":"T Damelang","year":"2019","unstructured":"Damelang, T., Rogerson, S. J., Kent, S. J. & Chung, A. W. Role of IgG3 in Infectious Diseases. Trends Immunol. 40, 197\u2013211 (2019).","journal-title":"Trends Immunol."},{"key":"545_CR22","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1542\/peds.80.6.933","volume":"80","author":"Y Asano","year":"1987","unstructured":"Asano, Y. et al. Immunoglobulin Subclass Antibodies to Varicefla-Zoster Virus. Pediatrics 80, 933\u2013936 (1987).","journal-title":"Pediatrics"},{"key":"545_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/infdis\/162.3.621","volume":"162","author":"Echevarr","year":"1990","unstructured":"Echevarr et al. Subclass Distribution of the Serum and Intrathecal IgG Antibody Response in Varicella-Zoster Virus Infections. J. Infect. Dis. 162, 621\u2013626 (1990).","journal-title":"J. Infect. Dis."},{"key":"545_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20496-3","volume":"12","author":"J Coignard","year":"2021","unstructured":"Coignard, J. et al. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1\/BRCA2 mutation carriers. Nat. Commun. 12, 1078 (2021).","journal-title":"Nat. Commun."},{"key":"545_CR25","doi-asserted-by":"publisher","first-page":"e1008064","DOI":"10.1371\/journal.ppat.1008064","volume":"15","author":"SI Richardson","year":"2019","unstructured":"Richardson, S. I. et al. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. PLoS Pathog. 15, e1008064 (2019).","journal-title":"PLoS Pathog."},{"key":"545_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-021-04017-w","volume":"599","author":"R Yamin","year":"2021","unstructured":"Yamin, R. et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature 599, 465\u2013470 (2021).","journal-title":"Nature"},{"key":"545_CR27","doi-asserted-by":"publisher","first-page":"ofw102","DOI":"10.1093\/ofid\/ofw102","volume":"3","author":"W Zhong","year":"2016","unstructured":"Zhong, W. et al. Antibody-Dependent Cell-Mediated Cytotoxicity to Hemagglutinin of Influenza A Viruses After Influenza Vaccination in Humans. Open Forum Infect. Dis. 3, ofw102 (2016).","journal-title":"Open Forum Infect. Dis."},{"key":"545_CR28","doi-asserted-by":"publisher","first-page":"11931","DOI":"10.1073\/pnas.1609316113","volume":"113","author":"W He","year":"2016","unstructured":"He, W. et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc. Natl Acad. Sci. USA 113, 11931\u201311936 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"545_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jim.2016.11.005","volume":"441","author":"P Sun","year":"2017","unstructured":"Sun, P. et al. NK cell degranulation as a marker for measuring antibody-dependent cytotoxicity in neutralizing and non-neutralizing human sera from dengue patients. J. Immunol. Methods 441, 24\u201330 (2017).","journal-title":"J. Immunol. Methods"},{"key":"545_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1442-200X.1991.tb01518.x","volume":"33","author":"T Ihara","year":"1991","unstructured":"Ihara, T. et al. Antibody response determined with antibody-dependent cell-mediated cytotoxicity (ADCC), neutralizing antibody, and varicella skin test in children with natural varicella and after varicella immunization. Acta Paediatr. Jpn 33, 43\u201349 (1991).","journal-title":"Acta Paediatr. Jpn"},{"key":"545_CR31","doi-asserted-by":"publisher","first-page":"11521","DOI":"10.1128\/JVI.01023-12","volume":"86","author":"M Bonsignori","year":"2012","unstructured":"Bonsignori, M. et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86, 11521\u201311532 (2012).","journal-title":"J. Virol."},{"key":"545_CR32","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/infdis\/jiw262","volume":"214","author":"S Jegaskanda","year":"2016","unstructured":"Jegaskanda, S. et al. Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge. J. Infect. Dis. 214, 945\u2013952 (2016).","journal-title":"J. Infect. Dis."},{"key":"545_CR33","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4049\/jimmunol.1400432","volume":"193","author":"S Jegaskanda","year":"2014","unstructured":"Jegaskanda, S., Reading, P. C. & Kent, S. J. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. J. Immunol. 193, 469\u2013475 (2014).","journal-title":"J. Immunol."},{"key":"545_CR34","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham, A. L. et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N. Engl. J. Med. 375, 1019\u20131032 (2016).","journal-title":"N. Engl. J. Med"},{"key":"545_CR35","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal, H. et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N. Engl. J. Med. 372, 2087\u20132096 (2015).","journal-title":"N. Engl. J. Med"},{"key":"545_CR36","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1172\/JCI121484","volume":"128","author":"MJ Levin","year":"2018","unstructured":"Levin, M. J. et al. Th1 memory differentiates recombinant from live herpes zoster vaccines. J. Clin. Invest 128, 4429\u20134440 (2018).","journal-title":"J. Clin. Invest"},{"key":"545_CR37","doi-asserted-by":"publisher","first-page":"e00240","DOI":"10.1128\/JVI.00240-21","volume":"95","author":"DS Schmid","year":"2021","unstructured":"Schmid, D. S. et al. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines. J. Virol. 95, e00240\u201300221 (2021).","journal-title":"J. Virol."},{"key":"545_CR38","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1016\/j.cell.2016.08.072","volume":"167","author":"LL Lu","year":"2016","unstructured":"Lu, L. L. et al. A functional role for antibodies in tuberculosis. Cell 167, e414 (2016).","journal-title":"Cell"},{"key":"545_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.smim.2018.05.003","volume":"39","author":"G Alter","year":"2018","unstructured":"Alter, G., Ottenhoff, T. H. M. & Joosten, S. A. Antibody glycosylation in inflammation, disease and vaccination. Semin. Immunol. 39, 102\u2013110 (2018).","journal-title":"Semin. Immunol."},{"key":"545_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jim.2018.11.002","volume":"464","author":"E Gonzalez-Gonzalez","year":"2019","unstructured":"Gonzalez-Gonzalez, E. et al. Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc region. J. Immunol. Methods 464, 87\u201394 (2019).","journal-title":"J. Immunol. Methods"},{"key":"545_CR41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/QAI.0000000000002105","volume":"82","author":"CS Tan","year":"2019","unstructured":"Tan, C. S., Ghofrani, J., Geiger, E., Koralnik, I. J. & Jost, S. Brief Report: Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors. J. Acquir Immune Defic. Syndr. 82, 220\u2013224 (2019).","journal-title":"J. Acquir Immune Defic. Syndr."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00545-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T22:22:55Z","timestamp":1678400575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00545-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00545-2","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"assertion":[{"value":"31 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.W. receives grants from G.S.K. and Merck and personal fees from Merck and Seqirus. M.J.L. received research grants from G.S.K., Merck, Moderna, and Saol Therapeutics (moneys to University of Colorado School of Medicine) and personal fees for Advisory Boards for Merck, G.S.K., Pfizer, and Curevo). S.Y.P., J.C., M.J. and D.S.S. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}